EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody–Drug Conjugates, and Targeted Therapies

Seiji Mabuchi, Ai Kusakabe, Yumi Takimoto iD

Current Oncology · 2026

DOI: 10.3390/curroncol33100622 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, 2026. Verfasst von Seiji Mabuchi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Hyogo Medical University, 1-1, Mukogawa-Cho, Nishinomiya 663-8501, Japan. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Immunotherapy, Immunoconjugates, Molecular Targeted Therapy. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Platinum-resistant ovarian cancer (PROC) has historically been treated with sequential non-platinum chemotherapy, with bevacizumab added when appropriate. The therapeutic landscape has expanded with positive randomized phase III data for pembrolizumab plus weekly paclitaxel with or without bevacizumab (KEYNOTE-B96), mirvetuximab soravtansine (MIRV) in FRα-high disease (MIRASOL), and relacorilant plus nab-paclitaxel (ROSELLA). Trastuzumab deruxtecan (T-DXd) has also shown substantial activity in previously treated HER2-expressing ovarian cancer, although its ovarian cohort was small, nonrandomized, and not restricted to PROC. These trials enrolled different populations and do not establish a cross-trial efficacy hierarchy. We therefore review the development of immunotherapy leading to KEYNOTE-B96, compare newer strategies with established PROC treatments, distinguish phase III evidence from regulatory approval and routine availability, and propose an evidence-informed framework for treatment selection and sequencing. The framework prioritizes current treatment opportunity while accounting for biomarker eligibility, prior treatment, residual toxicity, treatment and financial burden, patient priorities, and the feasibility of later-line therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsImmunotherapyImmunoconjugatesMolecular Targeted TherapyHumansFemaleDrug Resistance, Neoplasm

Stichwörter der Autor:innen

antibody–drug conjugatesbiomarkersimmunotherapyplatinum-resistant ovarian cancertargeted therapytreatment sequencing

Substanzen

Immunoconjugates

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Hyogo Medical University, 1-1, Mukogawa-Cho, Nishinomiya 663-8501, Japan.

ORCID-Profile: Yumi Takimoto

Zitieren

APA

Mabuchi, S., Kusakabe, A., & Takimoto, Y. (2026). A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody–Drug Conjugates, and Targeted Therapies. Current Oncology. https://doi.org/10.3390/curroncol33100622

Vancouver

Mabuchi S, Kusakabe A, Takimoto Y. A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody–Drug Conjugates, and Targeted Therapies. Current Oncology. 2026. doi:10.3390/curroncol33100622

BibTeX
@article{Mabuchi2026,
  author = {Mabuchi, Seiji and Kusakabe, Ai and Takimoto, Yumi},
  title = {A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody–Drug Conjugates, and Targeted Therapies},
  journal = {Current Oncology},
  year = {2026},
  doi = {10.3390/curroncol33100622}
}
Kostenlos starten →